Compare Stocks → “The Biggest Bubble of All Time” – Here’s What to Do. (From Chaikin Analytics) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AXLANASDAQ:AYLANASDAQ:FENCNASDAQ:INMB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXLAAxcella Health$0.40-8.9%$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,700 shsAYLAAyala Pharmaceuticals$0.48$0.36▼$7.31$7.46M1.9876,300 shs137,700 shsFENCFennec Pharmaceuticals$9.27+2.2%$10.05$6.30▼$11.92$251.22M0.38114,155 shs45,443 shsINMBINmune Bio$10.78+1.5%$11.46$6.50▼$14.74$196.20M1.9996,240 shs62,051 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXLAAxcella Health0.00%0.00%0.00%0.00%-96.27%AYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%FENCFennec Pharmaceuticals-1.84%-6.49%-17.55%-12.96%+14.09%INMBINmune Bio+4.73%+25.98%-9.31%-10.08%+50.64%“The Biggest Bubble of All Time” – Here’s What to Do. (Ad)Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.Just click here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXLAAxcella HealthN/AN/AN/AN/AN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AFENCFennec Pharmaceuticals2.4714 of 5 stars3.50.00.00.02.42.51.9INMBINmune Bio1.2047 of 5 stars3.51.00.00.02.31.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXLAAxcella HealthN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/AFENCFennec Pharmaceuticals3.00Buy$17.3386.98% UpsideINMBINmune Bio3.00Buy$16.0048.42% UpsideCurrent Analyst RatingsLatest AXLA, FENC, AYLA, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXLAAxcella HealthN/AN/AN/AN/A$1.42 per shareN/AAYLAAyala Pharmaceuticals$3.51M0.00N/AN/A$2.45 per share0.00FENCFennec Pharmaceuticals$21.25M11.82N/AN/A($0.43) per share-21.56INMBINmune Bio$160K1,226.23N/AN/A$2.07 per share5.21Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXLAAxcella Health-$81.19M-$19.25N/A∞N/AN/AN/A-259.91%N/AAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/AFENCFennec Pharmaceuticals-$16.05M-$0.61N/A13.24N/A-75.50%N/A-73.64%5/9/2024 (Estimated)INMBINmune Bio-$30.01M-$1.67N/A∞N/A-19,360.00%-64.11%-45.57%5/1/2024 (Estimated)Latest AXLA, FENC, AYLA, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023INMBINmune BioN/A-$0.47-$0.47-$0.47N/A$0.03 million3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXLAAxcella HealthN/AN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXLAAxcella HealthN/A0.800.80AYLAAyala PharmaceuticalsN/A2.282.28FENCFennec PharmaceuticalsN/A3.563.27INMBINmune BioN/A2.162.16OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXLAAxcella Health65.07%AYLAAyala Pharmaceuticals22.10%FENCFennec Pharmaceuticals55.51%INMBINmune Bio12.72%Insider OwnershipCompanyInsider OwnershipAXLAAxcella Health2.20%AYLAAyala Pharmaceuticals3.60%FENCFennec Pharmaceuticals11.25%INMBINmune Bio36.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAXLAAxcella Health112.95 million2.88 millionOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableFENCFennec PharmaceuticalsN/A27.10 million24.05 millionOptionableINMBINmune Bio1118.20 million11.63 millionOptionableAXLA, FENC, AYLA, and INMB HeadlinesSourceHeadlineINmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - April 25 at 9:00 AMINmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assayglobenewswire.com - April 23 at 8:00 AMINmune Bio rises 2%, on $4.5M direct offeringmsn.com - April 22 at 3:42 PMINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offeringfinance.yahoo.com - April 22 at 10:41 AMINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offeringglobenewswire.com - April 22 at 8:00 AMINmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interestamericanbankingnews.com - April 16 at 5:34 AMINmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024finance.yahoo.com - April 8 at 8:33 AMINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024globenewswire.com - April 8 at 8:00 AMAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)markets.businessinsider.com - April 2 at 11:32 PMINmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 1 at 12:16 PMINmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - March 31 at 10:18 AMINmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 30 at 2:42 PMINmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancementsfinance.yahoo.com - March 29 at 7:30 PMINmune Bio, Inc.: INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Updatefinanznachrichten.de - March 29 at 9:29 AMINmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Updateglobenewswire.com - March 28 at 4:01 PMINmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28globenewswire.com - March 26 at 4:01 PMINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapyglobenewswire.com - March 13 at 8:00 AMINmune Bio, Inc.: INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XProfinanznachrichten.de - March 6 at 7:23 PMBuy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developmentsmarkets.businessinsider.com - March 6 at 7:23 PMINmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™globenewswire.com - March 5 at 8:00 AMINMB Jun 2024 25.000 callfinance.yahoo.com - February 17 at 10:36 PMINMB Mar 2024 20.000 callfinance.yahoo.com - February 16 at 9:33 PMINMB Mar 2024 12.500 putfinance.yahoo.com - February 16 at 9:33 PMINMB Feb 2024 15.000 putfinance.yahoo.com - February 15 at 12:38 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAxcella HealthNASDAQ:AXLAAxcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Ayala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03 develop pre-clinical data in cancer that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.